Articles for Clinical

The FDA has approved Genentech’s Rituxan Hycela for subcutaneous injection for the treatment of certain blood cancers. Rituxan Hycela has similar outcomes as Rituxan, but can be delivered in 5 to 7 minutes compared with 1.5 hours for Rituxan.
A phase 3 clinical trial of patients with relapsing multiple sclerosis and primary progressive multiple sclerosis found that Ocrevus (ocrelizumab) significantly reduced disease progression, according to results released by Genentech.
The FDA has approved the use of Janssen Biotech, Inc’s immunotherapy Darzalex in combination with pomalidomide and dexamethasone. Darzalex is used to treat multiple myeloma patients who have previously received at least 2 therapies with lenalidomide and a proteasome inhibitor.
The FDA has approved Baxdela, a drug intended to treat adults with acute bacterial skin and skin structure infections caused by susceptible bacteria. Baxdela is also effective in treating MRSA and against other gram-positive or gram-negative pathogens.
According to a research study published in the journal Cancer, Asian women are less likely than non-Hispanic white women to receive timely follow-up after an abnormal screening mammogram.
With more women dying annually from chronic obstructive pulmonary disease (COPD) than men since 2000, researchers have examined trends in COPD hospitalization and in-hospital mortality, evaluating for differences by sex and race. They presented their research at the American Thoracic Society 2017 International Conference.
Panelists Peter L. Salgo, MD; Charles Wykoff, MD, PhD; and Jared Nielsen, MD, describe the mechanism of action and role of anti-VEGF therapies in the treatment of wet age-related macular degeneration.
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST